Cancer medicine · 2025
A New Model to Predict Survival Time in Patients With Hepatocellular Carcinoma With BCLC Advanced Stage.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ninomiya Masashi, Tsuruoka Mio, Inoue Jun, Hiraoka Atsushi, Sano Akitoshi, Sato Kosuke, Onuki Masazumi, Sawahashi Satoko, Ouchi Keishi, Watanabe Kengo, Kuroda Hidekatsu, Oikawa Takayoshi, Abe Tamami, Fujita Masashi, Abe Kazumichi, Katsumi Tomohiro, Sato Wataru, Igarashi Go, Iino Chikara, Tanabe Nobukazu, Numao Hiroshi, Ohira Hiromasa, Ueno Yoshiyuki, Masamune Atsushi
Аннотация
The variety of treatments available makes it difficult to determine whether a treatment would be effective for an individual case in advanced-stage hepatocellular carcinoma. We aimed to establish a new model of survival prediction in patients to establish standards in the recent and coming multimolecular targeted agents era. This analysis was prepared using a data set of 518 patients diagnosed with hepatocellular carcinoma prior to 2017. Multiple regression analysis showed the size of the largest tumor nodule, the number of nodules, macrovascular invasion, extrahepatic metastasis, total bilirubin, albumin, prothrombin time (PT), α-fetoprotein, and des-γ-carboxyprothrombin (DCP) as independent predictors of survival. A Weibull model had the best fit and, based on these predictors, we established two new predicted survival models with or without incorporating PT and DCP. This model is useful for planning and evaluating the efficacy of recent sequential therapies in the multimolecular targeted agents era.